| | |
5-HIAA
|
HVA
|
MHPG
|
---|
HTR3A Genotype
|
Sex
|
n
|
Mean ± SD (nmol/L)
|
Fa pa
|
Fb pb
|
Mean ± SD (nmol/L)
|
Fa pa
|
Fb pb
|
Mean ± SD (nmol/L)
|
Fa pa
|
Fb pb
|
---|
T/Tc
|
All
|
3
|
105 ± 52
|
F = 5.75
|
F = 10.22
|
203 ± 124
|
F = 3.25
|
F = 7.95
|
44 ± 5
|
F = 0.45
|
F = 0.29
|
C/Tc
| |
27
|
117 ± 36
|
p = 0.02
|
p = 0.002
|
211 ± 67
|
p = 0.07
|
p = 0.006
|
43 ± 8
|
p = 0.50
|
p = 0.75
|
C/C
| |
60
|
90 ± 35
| | |
166 ± 71
| | |
42 ± 7
| | |
T/Tc
|
Men
|
1
|
52
|
F = 0.31
|
F = 0.96
|
113
|
F = 0.75
|
F = 1.49
|
49
|
F = 0.20
|
F = 0.49
|
C/Tc
| |
11
|
106 ± 33
|
p = 0.58
|
p = 0.33
|
193 ± 50
|
p = 0.39
|
p = 0.23
|
44 ± 9
|
p = 0.66
|
p = 0.49
|
C/C
| |
40
|
90 ± 37
| | |
159 ± 11
| | |
43 ± 7
| | |
T/Tc
|
Women
|
2
|
131 ± 34
|
F = 8.55
|
F = 9.75
|
248 ± 137
|
F = 2.49
|
F = 4.05
|
41 ± 3
|
F = 0.68
|
F = 1.00
|
C/Tc
| |
16
|
124 ± 37
|
p = 0.006
|
p = 0.004d
|
224 ± 76
|
p = 0.12
|
p = 0.05e
|
42 ± 7
|
p = 0.42
|
p = 0.32f
|
C/C
| |
20
|
92 ± 30
| | |
179 ± 64
| | |
40 ± 6
| | |
- 5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c T/T and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 5.56, p = 0.02. e Correction for use of oral contraceptives, F = 1.76, p = 0.19. f Correction for use of oral contraceptives, F = 0.17, p = 0.68. Analysing heterosis, i.e. comparing homo- vs heterozygotes: All subjects 5-HIAA: F = 10.03, p = 0.002 (F = 5.71, p = 0.02 after correction for back length). All subjects HVA: F = 7.13, p = 0.009 (F = 2.28, p = 0.10). Men 5-HIAA: F = 1.96, p = 0.17 (F = 1.00, p = 0.32). Men HVA: 2.33, p = 0.13 (F = 1.40, p = 0.24). Women 5-HIAA: F = 6.73, p = 0.01 (F = 5.65, p = 0.02 and F = 3.76, p = 0.06 corrected for back length and use of oral contraceptives, respectively). Women HVA: F = 2.49, p = 0.12 (F = 1.03, p = 0.32 and F = 0.98, p = 0.33 corrected for back length and use of oral contraceptives, respectively).